NDAORALTABLETPriority Review
Approved
Nov 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
STROMECTOL (ivermectin) by Merck & Co.. Approved for antiparasitic [epc]. First approved in 1996.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STROMECTOL (ivermectin) is an oral antiparasitic tablet approved by Merck & Co. in 1996 for treating parasitic infections. It is a small-molecule agent that works by disrupting parasitic neuromuscular function, leading to paralysis and death of susceptible organisms. The drug is indicated for various parasitic conditions including onchocerciasis, strongyloidiasis, and other helminthic infections.
$0.002BPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal Part D utilization, suggesting a mature market with declining commercial opportunity and likely reduced team investment.
Mechanism of Action
Pharmacologic Class:
Antiparasitic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
Started Sep 2025
20,000 enrolled
Soil-Transmitted Helminths
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Started Oct 2023
34 enrolled
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis
Started Mar 2022
60 enrolled
Pediculosis
Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for the Treatment of Scabies
Started Jun 2021
100 enrolled
Scabies
Rosacea and Ivermectin
Started Apr 2021
30 enrolled
Rosacea
Worked on STROMECTOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.